Lorglumide sodium salt
Cat. No.：YN321656
| 产品名称: | Lorglumide sodium salt |
| CAS No.: | 1021868-76-7 |
| Chemical Name: | 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxo-pentanoic acid, monosodium salt |
| Synonyms: | CR-1409 sodium salt |
| 分子量: | 481.39 |
| 分子式: | C₂₂H₃₁Cl₂N₂NaO₄ |
| SMILES: | ClC1=C(C=CC(C(NC(CCC(O[Na])=O)C(N(CCCCC)CCCCC)=O)=O)=C1)Cl |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Lorglumide sodium salt (CR-1409 sodium salt) 是一种有效的胆囊收缩素（CCK）受体拮抗剂。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Sabbatini, M.E., Chen, X., Ernst, S.A., et al.Rap1 activation plays a regulatory role in pancreatic amylase secretionJ. Biol. Chem.,(2008)
Murphy, K.G., and Bloom, S.R.Gut hormones in the control of appetiteExp. Physiol.89(5),507-516(2004)
Wynne, K., Stanley, S., and Bloom, S.The gut and regulation of body weightJ. Clin. Endocrinol. Metab.89(6),2576-2582(2004)
Makovec, F., Peris, W., Revel, L., et al.Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivativesJ. Med. Chem.35(1),28-38(1992)
Barthó, L., Holzer, P., Lembeck, F., et al.Evaluation of a new and potent cholecystokinin antagonist on motor responses of the guinea-pig intestineBr. J. Pharmacol.90,753-761(1987)
Niederau, C., Liddle, R.A., Williams, J.A., et al.Pancreatic growth: Interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in miceGut28,63-69(1987)
Scarpignato, C., Varga, G., Dobronyi, I., et al.Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the ratBr. J. Pharmacol.96,661-669(1989)
Gamble, J., Kenny, S., and Dockray, G.J.Plasminogen activator inhibitor (PAI)-1 suppresses inhibition of gastric emptying by cholecystokinin (CCK) in miceRegul. Pept.185,9-13(2013)
Lo, C.C., Davidson, W.S., Hibbard, S.K., et al.Intraperitoneal CCK and fourth-intraventricular Apo AIV require both peripheral and NTS CCK1R to reduce food intake in male ratsEndocrinology155(5),1700-1707(2014)
